Adnkronos Rome, October 10 (Adnkronos Salute) – "I believe that collaboration between the public and private sectors is essential. The shared goal is patient well-being, and research requires a long timeframe and long-term investment that unfortunately the public sector cannot guarantee: results must be seen within two or three years at most. In the private sector, however, companies have long-term plans; a drug can take up to ten years.
This result is achieved thanks to the collaboration between the doctor who works in the public sector and the private company." So said Andrea Giaccari, diabetologist at the Policlinico A. Gemelli in Rome, speaking at the Investigator's Meeting event held in Rome on various areas of clinical research that AstraZeneca conducts in Italy.
"Diabetology research is very important because the diagnosis of diabetes, which is based on elevated blood sugar or glycated hemoglobin levels," Giaccari explains, "carries risks of specific and cardiovascular complications that the patient isn't aware of, but that clinicians are well aware of." In this regard, the expert emphasizes that "when a person is diagnosed with diabetes, they think about their blood sugar levels and how to reduce them, but we doctors think about their future. It's crucial to convey this vision not only to patients, but also to institutions and the scientific community," and to make them understand "that this diagnosis implies the need for long-term treatment. Only through collaboration between institutions, clinicians, researchers, and private companies," he concludes, "is it possible to guarantee effective and long-lasting treatment paths."